Withdrawal of naftidrofuryl infusion (Praxilene Forte)Following a review conducted in the UK and Europe, intravenous naftidrofuryl is being withdrawn. Thisproduct was previously available for the treatment of severe peripheral vascular disease but serious adversereactions have been reported1. The risks of cardiac and neurological toxicity have been found to outweighthe benefit of intravenous naftidrofuryl in this condition. The oral form of naftidrofuryl (Praxilene capsules100mg) remains available for use under the conditions stated in the data sheet.1.
CSM/MCA. Current Problems in Pharmacovigilance 1995; 21:
We use cookies and similar technologies for the following purposes:
Do you accept cookies and these technologies?
We use cookies and similar technologies for the following purposes:
Do you accept cookies and these technologies?